To directly compare the effects of VEGF-A, Ang-2, and dual inhibition on glioma biology, we tested the effects of these three antibodies vs. control antibody in an identical, clinically relevant dose (5 mg/kg BW every third day) (for treatment groups, see Figure S1A). The gene discussed is ANGPT2; the disease is glioma.